FOXO1 acts as a direct upstream regulator of NCOA4, inhibiting NCOA4‐mediated ferritinophagy and alleviating cisplatin‐induced SGN ferroptosis and hearing loss. Here, FOXO1 is linked to hearing loss disorder.